Article
Dr. Jack Cush reviews this past week's news on RheumNow.com and suggests a learning plan for those wanting to consume the upcoming ACR Convergence 2023 meeting.
All News
Article
Safety risks found in a postmarketing trial with the Janus-associated kinase (JAK) inhibitor tofacitinib (Xeljanz) appear to have influenced prescribing patterns across the class for rheumatoid arthritis (RA) patients in the Veterans Affairs (VA) health system, researchers found.
Article
Dr. Jack Cush reviews the big PMR reports from this week along with other journal reports from RheumNow.com.
Article
This week on the podcast, Dr. Jack Cush is joined by special guest, Dr. Kathryn Dao to review the news and journal reports from the past week on RheumNow.com. They discuss unmet needs in gout, obesity and CV disease in PsA and should you check ANCA antibodies in SLE?
Article
A large cohort analysis of insured rheumatoid arthritis (RA) patients reveals that RA patients have a 1.69 to 2.08 fold higher risk of developing cancer, especially lymphoma or lung cancer, within 1 year of RA diagnosis.
Article
This week, Dr. Jack Cush reviews the news with special guest, Dr. Janet Pope. They discuss "Not-non-Inferior", large scale genetic screening, Zoster risk w/ newer lupus drugs, tapering, RA referral problems and the TNR webinar session on "ORAL Surveillance Revisited".
Article
The safety of abatacept was studied using patients with rheumatoid arthritis (RA) from 7 European registers, revealing safety signals on par with that previously reported with no new safety concerns.
Article
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. This week highlights Veterans, Vegetarians and Antenatal Corticosteroids.
Article
Dr. Jack Cush Reviews the news and journal reports on CVA, TKA, PJP, ADA, and more!
Article
A safety analysis of six phase III SELECT trials showed that higher-risk rheumatoid arthritis (RA) patients had an increased risk of MACE, malignancy (excluding NMSC) and venous thromboembolic events (VTE) regardless of being treated with either upadacitinib (UPA) or adalimumab (ADA).
Article
While it is known that rheumatoid arthritis (RA) patients may be at risk for certain cancers, the question is which cancers and is this modified by therapy.
Article
A multinational registry analysis of rheumatoid arthritis (RA) receiving abatacept (ABA) has shown that the safety profile of ABA remains unchanged with no new or increased risks of infection or malignancy.
Aurelie Najm
Tweet
2 RA cohorts w/Breast Cancer
17% TNFi within 1yr after surgery
No diff in overall survival at 5 yr w/ TNFi or csDMARD
Trend towards better BC specific survival w/ TNFi vs. csDMARD only
Worst survival for GC>7.5mg/day
Only 2 yrs follow up
@RheumNow #ACR23 ABST1675 https://t.co/ekKlJ2dP5i
Nouf Al hemmadi
Tweet
1-Can we prevent RA ? Vagotomy?
2-CV events in auto immune rheumatic disease pregnancies.
3-CVS vasculitis , challenges and role of Brain biopsy
And others……..
https://t.co/BX8bDSX1M3
@RheumNow , daily recap
#ACR23
Mike Putman
Tweet
No more underpowered long-term safety studies
We need a "SELECT-SURVEILLANCE" study to replicate ORAL-SURVEILLANCE & tell us if UPA has the same MACE/cancer risk as TOFA
Minus that, I plan to go 100% TOFA when it becomes generic in 2026
@RheumNow #ACR23 Abstr1326 https://t.co/LyQ1Q8qReO
Mike Putman
Tweet
Yet another (mostly) reassuring report about lymphoma and DMARDS
The skin cancer signal in the CIRT trial was weird; would be worth looking into that in observational studies as well @NamrataRheum
#ACR23 Abst0438 @RheumNow https://t.co/Beg8UUe2mn
Mike Putman
Tweet
Nice VA study evaluating risk of lung cancer w/respect to RA treatment strategies
Take home? No association. Aside from the (small risk) w/JAKi's, I think malignancy risks have been mostly overblown
@NamrataRheum @RheumNow ABST0453 #ACR23 https://t.co/lDz0nV1KHt
Dr. John Cush
Tweet
Biologics, #RA and Risk of skin CA (NMSC) is complex.
- RA alone is a risk for NMSC
49K study of ABA & NMSC ;
- In RCTs, risk same w/ ABA & PBO
- Registries & Claims data: equal w/ ABA, csDMARDs. b/tsDMARDs
- Pooled obs data shows slight ABA risk https://t.co/tp6F0cJWug https://t.co/u6UdAUZqoc
Dr. John Cush
Tweet
Johns Hopkins & Univ Pittsburgh Scleroderma compared autoantibodies in 676 SSc pts w/ hx of cancer to 687 SSc controls without CA. Anti-POLR3 & anti-Ro52 assoc w. significantly increased cancer risk; Centromere & U1RNP had a decreased cancer risk https://t.co/z6HfRR7PWs https://t.co/zISZlgHGjd
Dr. John Cush
Tweet
Cancer Risk From RA, Not the Drugs
A large US claims analysis shows RA patients were nearly 2 times more likely (than those without RA) to develop lymphoma or lung cancer and that commonly used RA treatments were also unlikely to increase cancer risk.
https://t.co/6yrc0TsT53 https://t.co/WRQzeFoR1Z
